98%
921
2 minutes
20
Introduction: Lean Type 2 diabetes mellitus (T2DM), defined as individuals with body mass index (BMI) < 25 kg/m, presents distinct clinical and biochemical characteristics across populations, particularly in Africa. This review assessed the prevalence and clinical-biochemical profiles of lean T2DM in Africa, aiming to improve understanding and management strategies.
Methods: This systematic review and meta-analysis involved 11 observational studies on lean T2DM in African adults. Specific BMI definitions [<25 Kg/m] and clinical parameters were assessed, while non-observational studies were excluded. Data was analysed using STATA 18.
Results: The pooled prevalence of lean T2DM in African populations was 38.5 % (95 % CI: 26.8 %-50.9 %, I2 = 96.71 %, p < 0.001]). Clinical characteristics reveal a mean age of 48.35 years and a pooled mean BMI of 25.45 kg/m. Metabolic assessments indicated raised HbA1c levels with a pooled median 9.34 % [95 %CI: 8.60-10.08 %, I2 = 97.44 %, p < 0.001]). Insulin resistance was low, as indicated by HOMA2-IR levels.
Conclusions: This review revealed a high prevalence of lean T2DM in Africa and identified unique clinical and biochemical characteristics. The findings suggest a potential need for more tailored approaches in assessing this phenotype, which remains underrepresented in current guidelines. Larger, well-designed studies are needed to strengthen the evidence base and inform effective treatment strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.diabres.2025.112406 | DOI Listing |
J Endocrinol
September 2025
University of Missouri, Columbia, MO.
Purpose: CL316,243 (CL), a beta 3 adrenergic receptor (B3-AR) agonist has 'exercise mimetic' effects in adipose tissue (AT). CL may also positively affect skeletal muscle (SM), yet the role of estrogen receptor beta (ERβ) in mediating SM-specific effects of CL is not known. We investigated the effects of CL on SM metabolism, as well as the role played by ERβ.
View Article and Find Full Text PDFEClinicalMedicine
October 2025
Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity. However, it remains inconclusive whether the combination of lifestyle modifications and GLP-1RA interventions can lead to greater weight loss and better control of cardiovascular biomarkers. We aimed to evaluate the efficacy of this combination therapy on weight loss and cardiometabolic markers in adults with overweight or obesity.
View Article and Find Full Text PDFGeroscience
September 2025
Research Institute of the McGill University Health Centre, 2155 Guy Street, Suite 500, Montreal, QC, H3H 2R9, Canada.
Frailty, often linked to sarcopenia, involves reduced muscle strength and mass. While sarcopenia has multiple causes, impaired muscle protein synthesis may contribute. Leucine and resistance training (RT) are anabolic stimuli, but the long-term effects of leucine combined with RT in pre/frail older women remain unclear.
View Article and Find Full Text PDFJ Metab Bariatr Surg
August 2025
Division of Foregut Surgery, Korea University College of Medicine, Seoul, Korea.
Metabolic and bariatric surgery induces metabolic benefits beyond weight loss, including improved insulin sensitivity, type 2 diabetes (T2D) remission, and reduced inflammation. Recent metabolomics research highlights amino acid metabolites-branched-chain amino acids, aromatic amino acids, and tryptophan-derived compounds-as key biomarkers for predicting surgical outcomes. Elevated preoperative levels of isoleucine, phenylalanine, levodopa, and 3-hydroxyanthranilic acid are associated with improved glycemic control and T2D remission.
View Article and Find Full Text PDFAnn Pediatr Endocrinol Metab
August 2025
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Ever since its discovery, glucagon-like-peptide 1 (GLP-1) and drugs with similar function (collectively GLP-1s) have been used for type 2 diabetes mellitus and have been effective for obesity. Their profound effect on weight loss has resulted in widespread use of these medicines for treating obesity. Extensive studies have shown that GLP-1s decrease body weight, lean mass, and other metabolic phenotypes.
View Article and Find Full Text PDF